滚动资讯
FierceBiotechArtivion nabs PMA clearance for aortic stent graft system, triggers Endospan buyout optionFierceBiotechWith $2B Novo deal in the books, Vivtex isn't 'limited to being just a drug delivery company': CEOFierceBiotechAstellas unearths Dyno muscle disorder AAV capsid with $15M option agreementFierceBiotechAkari locks arms with WuXi XDC to develop and manufacture novel ADC treatmentBioPharma DiveActivist investor revives campaign to overhaul Novavax boardEndpoints NewsMerck adjusts its vaccine supply deal in China; Soleno withdraws EU applicationBioPharma DiveJeito Capital, prominent biotech investor, raises $1.2B for next fundEndpoints NewsGilead takes another big swing at expanding beyond HIVIlluminaGrail seeks EU damages, costs over illegal veto on Illumina deal - MLexBioWorldSononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeuticsEndpoints NewsInside the Talkspace-Universal Health Services dealLonza NewsImmuneOncia signs manufacturing agreement with Lonza for Danburstotug - Drug Discovery News
Agilent 2026年3月10日

安捷伦科技为何斥资9.5亿美元收购Biocare Medical（纽交所代码：A）——来自Seeking Alpha的报道

安捷伦科技为何斥资9.5亿美元收购Biocare Medical（纽交所代码：A）——来自Seeking Alpha的报道

原文
暂时没有全文，请查看原始来源。

目录

59 全部